FiercePharma7d
Supernus' 4th try proves the charm with long-awaited FDA approval for Parkinson's infusion pump Onapgo
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
Supernus: New Approval Holds Promise Of Increased Growth
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
BioSpace7d
Supernus Taps Potential $300M US Opportunity With FDA Win for Parkinson’s Drug-Device Combo
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...
Pharm Exec4d
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...
GlobalData on MSN6d
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...
New Atlas7d
US approves "milestone" Parkinson's treatment for 2025 release
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
Nasdaq8d
Supernus Pharmaceuticals Announces FDA Approval of ONAPGO, the First Subcutaneous Apomorphine Infusion Device for Parkinson's Disease in the U.S.
ONAPGO, a subcutaneous infusion device, treats motor fluctuations in advanced Parkinson's disease and launches in the U.S. in 2025. Supernus Pharmaceuticals has announced the FDA approval of ...
Yahoo Finance7d
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
Supernus will make ONAPGO available in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support at launch. “Continuous ...